Eton Pharmaceuticals, Inc. (ETON) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Eton Pharmaceuticals, Inc. (ETON): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 60/100 — a percentile rank of Eton Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $1.5B |
| P / E | 116.0× |
| P / S | 13.9× |
| EV / EBITDA | 70.6× |
| Gross margin | 57.9% |
| Operating margin | 15.4% |
| Net margin | 12.0% |
| Return on equity | 27.2% |
| ROIC | 34.1% |
| Revenue growth | 81.5% |
| Debt / equity | 0.6× |
| Dividend yield | 0.0% |
Is Eton Pharmaceuticals, Inc. overvalued? P/S looks overvalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Eton Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact